FactaeThe Factual News

Poxel presents results at EASD 2026 on Imeglimin

Poxel unveils data on Imeglimin against MASH at EASD 2026.

Published 4j1 sourceupdated 4j
Lire en français
≈ 12s

The fact

This presentation could impact the stock's valuation.

Investors await promising clinical results.

Click the link to read an article on the topic:
Explore this topic
What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.
FranceWorld map →
Follow topic →
Auto-synthesis from 1 media source · identified on August 20, 2026
← Back to home
Discover

Read more

All marches →
marches

Poxel announces end of phase 2 clinical trial for MASH on September 30

10h · 1 sourcemarches

Poxel postpones publication of its half-year financial results

3sem · 1 sourcemarches

Poxel secures Japanese patent for diabetes-targeting molecule

13sem · 1 sourcemarches

Poxel hit by Merck payment halt: clinical timeline impact

11sem · 1 sourcemarches

CAC 40 in wait-and-see mode before market reopening, several stocks decline

5h · 1 source